A neonate affected by a novel inactivating mutation in the calcium-sensing receptor (CASR) gene is presented. This mutation is homozygously inherited and has not been previously described. A deletion in exon 5 (c.1392_1404del13) of the gene causes a loss of function of the receptor, which results in neonatal severe hyperparathyroidism and an ensuing extreme hypercalcemia. In a case of homozygosis of the CASR gene, the use of cinacalcet is the second reported calcimimetic treatment attempt and the first treatment attempt prior to surgery. However, because of the type of mutation, parathyroid surgery was necessary at 4 months of age after therapeutic failure. Because there are multiple mutations that affect the CASR gene in different ways, treatment with cinacalcet as an alternative to surgery may be valuable in homozygous cases that are caused by different mutations than the reported case.

Keywords:
Calcimimetic, Cinacalcet, Hypercalcemia, Calcium-sensing receptor, Neonatal hyperparathyroidism, Parathyroidectomy, Familial hypocalciuric hypercalcemia
1.
Gussinyé M, Yeste D, Clemente M, et al: Actitud ante una hipercalcemia. Rev Esp Endocrinol Pediatr 2010;1:81-85.
2.
Bermúdez JA, Borrajo E, Rivas F, et al: Trastornos del metabolismo del Calcio; in Sociedad Española de Endocrinología Pediátrica (ed): Guías Diagnóstico-Terapéuticas en Endocrinología Pediátrica, ed 1. Madrid, Sociedad Española de Endocrinología Pediátrica, 2002, pp 1-28.
3.
Pearce SH, Trump D, Wooding C, et al: Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995;96:2683-2692.
4.
Cole D, Forsythe CR, Dooley JM, Grantmyre EB, Salisbury SR: Primary neonatal hyperparathyroidism: a devastating neurodevelopmental disorder if left untreated. J Craniofac Genet Dev Biol 1990;10:205-214.
5.
Ward DT: Calcium receptor-mediated intracellular signaling. Cell Calcium 2004;35:217-228.
6.
Hendy GN, D'Souza-Li L, Yang B, et al: Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 2000;16:281-296.
7.
Alon US, Van De Voorde RG: Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol 2010;25:1747-1750.
8.
Ward BK, Magno AL, Davis EA, et al: Functional deletion of the calcium-sensing receptor in a case of neonatal severe hyperparathyroidism. J Clin Endocrinol Metab 2004;89:3721-3730.
9.
Al-Shanafey S, Al-Hosaini R, Al-Ashwall A, et al: Surgical management of severe neonatal hyperparathyroidism: one center's experience. J Pediatr Surg 2010;45:714-717.
10.
Reh CM, Hendy GN, Cole DE, et al: Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J Clin Endocrinol Metab 2011;96:E707-E712.
11.
Wilhelm-Bals A, Parvex P, Magdelaine C, et al: Successful use of biphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 2012;129:e812-e816.
12.
Pearce SH, Trump D, Wooding C, et al: Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995;96:2683-2692.
13.
Gabbett MT, Jones K, Cowell CT, et al: Neonatal severe hyperparathyroidism: an important clue to the aetiology. J Paediatr Child Health 2006;42:813-816.
14.
Bai M, Pearce SH, Kifor O, et al: In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J Clin Invest 1997;99:88-96.
15.
Nyweide K, Feldman KW, Gunther DF, et al: Hypocalciuric hypercalcemia presenting as neonatal rib fractures. A newly described mutation of the calcium-sensing receptor gene. Pediatr Emerg Care 2006;22:722-724.
16.
Obermannova B, Banghova K, Sumnik Z, et al: Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur J Pediatr 2009;168:569-573.
17.
Jack MM, Stone ML, Clifton-Bligh R: Neonatal hypercalcemia due to polymorphisms of the calcium-sensing receptor. J Pediatr Endocrinol Metabol 2009;22:561-563.
18.
Aida K, Koishi S, Inoue M, et al: Familial hypocalciuric hypercalcemia associated with mutation in the human Ca2+-sensing receptor gene. J Clin Endocrinol Metab 1995;80:2594-2598.
19.
Chikatsu N, Fukumoto S, Suzawa M, et al: An adult patient with severe hypercalcemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Clin Endocrinol (Oxf) 1999;50:537-543.
20.
Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB: The role of calcium, calcitriol and their receptors in parathyroid regulation. Nefrología 2009;29:103-108.
21.
Olivar J, Pavón I, Iglesias P: Familiar hypocalciuric hypercalcemia: review of three cases. Endocrinol Nutr 2008;55:267-269.
22.
Ubetagoyena M, Castaño L, Pérez de Nanclares G, et al: Hipercalcemia hipocalciúrica familiar: a propósito de una nueva mutación. An Pediatr (Barc) 2011;74:47-50.
23.
Urán M, Alonso R, Moliner C, et al: Hipercalcemia por inmovilización en el niño críticamente enfermo: tratamiento con calcitonina. An Esp Pediatr 2001;54:555-558.
24.
Fox L, Sadowsky J, Pringle KP, et al: Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant. Pediatrics 2007;120:e1350-e1354.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.